Crohn disease；Plaque psoriasis；Psoriatic arthritis；Pustulosis palmaris et plantaris <2024/7/19>

Antipsoriatic Agent; Interleukin-23 Inhibitor; Monoclonal Antibody
Human IgG1 monoclonal antibody which selectively binds to the p19 subunit of interleukin (IL)-23, thereby inhibiting its interaction with the IL-23 receptor, resulting in inhibition of the release of proinflammatory cytokines and chemokines.

1.Onset of action: Psoriasis: Response best determined after 12 weeks.
2.Distribution: Vdss: Plaque psoriasis: 11.2 L; Crohn disease: 7.68 L.
3.Metabolism: Degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.
4.Half-life elimination: Plaque psoriasis: ~28 days; Crohn disease: ~21 days.
5.Time to peak: 3 to 14 days.

Serious hypersensitivity to risankizumab or any component of the formulation.

Fetal risk cannot be ruled out.

It is not known if risankizumab is present in breast milk.Infant risk cannot be ruled out.

fainting, dizziness, swelling of your face, eyelids, lips, mouth, tongue, or throat, chest tightness, skin rash, itching

Crohn disease, moderate to severe:
Induction: IV: 600 mg at weeks 0, 4, and 8.
Maintenance: SUBQ: Prefilled cartridge: 180 to 360 mg at week 12 and every 8 weeks thereafter; use lowest effective dosage to maintain therapeutic response.
Plaque psoriasis, moderate to severe:
SUBQ: Prefilled syringe and auto-injector: 150 mg at weeks 0, 4, and then every 12 weeks thereafter.
Psoriatic arthritis:
SUBQ: Prefilled syringe and auto-injector: 150 mg at weeks 0, 4, and then every 12 weeks thereafter; may be administered alone or in combination with non–biologic disease-modifying antirheumatic drugs.

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).